Trinity Biotech Announces Strategic Investment in Novus Diagnostics to Advance Rapid Sepsis Testing Platform
Trinity Biotech (TRIB) has announced a strategic investment in Novus Diagnostics, acquiring a 12.5% equity stake valued at $2.5 million through the issuance of 1.4 million ADS. The investment aims to accelerate the development of Novus' rapid sepsis testing platform, which promises 15-minute bloodstream infection test results. Current sepsis testing methods take days, while this point-of-care solution could transform diagnosis and treatment of a condition that affects 1.7 million people and causes 350,000 deaths annually in the U.S. The investment values Novus at $20 million post-investment.
Trinity Biotech (TRIB) ha annunciato un investimento strategico in Novus Diagnostics, acquisendo una partecipazione azionaria del 12,5% del valore di 2,5 milioni di dollari mediante l'emissione di 1,4 milioni di ADS. L'investimento mira ad accelerare lo sviluppo della piattaforma di test rapidi per la sepsi di Novus, che promette risultati dei test per le infezioni del flusso sanguigno in 15 minuti. I metodi attuali per il test della sepsi richiedono giorni, mentre questa soluzione point-of-care potrebbe trasformare la diagnosi e il trattamento di una condizione che colpisce 1,7 milioni di persone e causa 350.000 decessi all'anno negli Stati Uniti. L'investimento valuta Novus a 20 milioni di dollari post-investimento.
Trinity Biotech (TRIB) ha anunciado una inversión estratégica en Novus Diagnostics, adquiriendo una participación del 12,5% valorada en 2,5 millones de dólares mediante la emisión de 1,4 millones de ADS. La inversión tiene como objetivo acelerar el desarrollo de la plataforma de prueba rápida de sepsis de Novus, que promete resultados de pruebas de infecciones en el torrente sanguíneo en 15 minutos. Los métodos actuales de prueba de sepsis tardan días, mientras que esta solución en el punto de atención podría transformar el diagnóstico y tratamiento de una condición que afecta a 1,7 millones de personas y causa 350,000 muertes anuales en EE. UU. La inversión valora a Novus en 20 millones de dólares después de la inversión.
트리니티 바이오텍 (TRIB)이 노부스 다이그노스틱스에 전략적 투자를 발표하며, 250만 달러의 가치로 12.5% 지분을 확보하기 위해 140만 ADS를 발행했습니다. 이 투자는 노부스의 신속한 패혈증 검사 플랫폼 개발을 가속화하는 것을 목표로 하며, 15분 내에 혈류 감염 테스트 결과를 제공합니다. 현재 패혈증 검사 방법은 며칠이 걸리지만, 이 현장 진료 솔루션은 170만 명에 영향을 미치고 매년 미국에서 35만 명이 사망하는 상황의 진단 및 치료를 혁신할 수 있습니다. 이 투자로 노부스의 가치는 2천만 달러가 됩니다.
Trinity Biotech (TRIB) a annoncé un investissement stratégique dans Novus Diagnostics, acquérant une participation de 12,5% d'une valeur de 2,5 millions de dollars par l'émission de 1,4 million d'ADS. Cet investissement vise à accélérer le développement de la plateforme de tests rapides pour la septicémie de Novus, qui promet des résultats de tests d'infection sanguine en 15 minutes. Les méthodes actuelles de test de la septicémie prennent des jours, alors que cette solution de soins immédiats pourrait transformer le diagnostic et le traitement d'une affection qui touche 1,7 million de personnes et entraîne 350 000 décès chaque année aux États-Unis. Cet investissement valorise Novus à 20 millions de dollars après l'investissement.
Trinity Biotech (TRIB) hat eine strategische Investition in Novus Diagnostics angekündigt und sich eine Beteiligung von 12,5% im Wert von 2,5 Millionen US-Dollar durch die Emission von 1,4 Millionen ADS gesichert. Die Investition soll die Entwicklung der schnellen Sepsis-Testplattform von Novus beschleunigen, die Testergebnisse für Blutstrominfektionen in 15 Minuten verspricht. Die derzeitigen Testmethoden für Sepsis dauern Tage, während diese Point-of-Care-Lösung die Diagnose und Behandlung einer Erkrankung revolutionieren könnte, die 1,7 Millionen Menschen betrifft und jährlich 350.000 Todesfälle in den USA verursacht. Nach der Investition wird Novus mit 20 Millionen US-Dollar bewertet.
- Strategic acquisition of 12.5% stake in innovative sepsis testing technology
- Entry into $50 billion annual sepsis-related hospitalization market in the U.S.
- Platform addresses key limitations in current sepsis diagnostics with 15-minute results vs. days
- Dilution of existing shareholders through issuance of 1.4 million ADS
- Significant investment ($2.5M) in early-stage technology without immediate revenue
Insights
Trinity Biotech's strategic investment in Novus Diagnostics represents a significant move into the high-potential sepsis diagnostics market. The
The technology's key advantage lies in its rapid turnaround time and ability to work despite prior antibiotic use, potentially reducing the
For a micro-cap company with a
The global sepsis diagnostics market is projected for substantial growth, driven by increasing healthcare costs and aging populations. Trinity's dual acquisition strategy, including both Novus and EpiCapture, signals a strategic pivot toward high-value diagnostic platforms. The company's stock-based transaction structure effectively leverages its public listing to acquire promising technologies without straining its balance sheet.
DUBLIN, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced a strategic investment in Novus Diagnostics, a company pioneering a rapid sepsis testing platform. This investment will accelerate the development and commercialization of Novus’ groundbreaking point-of-care diagnostic solutions, including its 15-minute bloodstream infection test.
Sepsis is a life-threatening condition resulting from the body’s overwhelming response to infection. According to the Centers for Disease Control and Prevention (CDC) it is estimated to affect 1.7 million people and cause approximately 350,000 deaths annually in the U.S. alone. Timely and accurate diagnosis is critical for improving patient outcomes, yet current testing methods are slow, often taking days to deliver results. Novus are developing an innovative bedside test that can deliver rapid sepsis diagnoses, a solution that could transform the management of this life-threatening condition.
“Rapid sepsis diagnosis has long been considered one of the ‘holy grails’ in diagnostics. With Novus Diagnostics’ platform, we are one step closer to that goal,” stated John Gillard, President and Chief Executive Officer of Trinity Biotech. “Our investment not only underscores our commitment to addressing urgent clinical challenges but also leverages our strengths in manufacturing, regulatory affairs, and commercialization to help bring this crucial diagnostic tool to market. We are confident that, with our support, Novus will be able to accelerate its path to regulatory approval and launch.”
Novus’ platform addresses key limitations in current sepsis diagnostics, such as the delay in results and the inaccuracies caused by contamination and prior antibiotic use. This rapid, point-of-care solution is expected to significantly improve sepsis outcomes by enabling faster diagnosis and timely treatment, potentially saving lives and reducing the over
Keith O’Neill, CEO of Novus Diagnostics, commented, "We are thrilled to have Trinity Biotech as a strategic investor. Their technical expertise, regulatory experience, and manufacturing capabilities will be instrumental in helping us bring our rapid sepsis diagnostic platform to market. Together, we aim to revolutionize sepsis care and, ultimately, improve patient outcomes."
Trinity Biotech has acquired a
Separately, Trinity Biotech also today announced the acquisition of EpiCapture Limited – a company developing a non-invasive test for monitoring the risk of aggressive prostate cancer – a copy of the press release reporting the acquisition can be found on our website www.trinitybiotech.com.
Forward-Looking Statements
This release includes statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”), including but not limited to statements related to Trinity Biotech’s cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations. Trinity Biotech claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterised by the terms “may,” “believes,” “projects,” “expects,” “anticipates,” or words of similar import, and do not reflect historical facts. Specific forward-looking statements contained in this release may be affected by risks and uncertainties, including, but not limited to, our ability to capitalize on our purchase of the assets of Waveform, our continued listing on the Nasdaq Stock Market, our ability to achieve profitable operations in the future, the impact of the spread of COVID-19 and its variants, potential excess inventory levels and inventory imbalances at the company’s distributors, losses or system failures with respect to Trinity Biotech’s facilities or manufacturing operations, the effect of exchange rate fluctuations on international operations, fluctuations in quarterly operating results, dependence on suppliers, the market acceptance of Trinity Biotech’s products and services, the continuing development of its products, required government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Trinity Biotech’s intellectual property or claims of infringement of intellectual property asserted by third parties and risks related to condition of the United States economy and other risks detailed under “Risk Factors” in Trinity Biotech’s annual report on Form 20-F for the fiscal year ended December 31, 2023 and Trinity Biotech’s other periodic reports filed from time to time with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statements were made. Trinity Biotech does not undertake and specifically disclaims any obligation to update any forward-looking statements.
About Trinity Biotech
Trinity Biotech is a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has recently entered the wearable biosensor industry, with the acquisition of the biosensor assets of Waveform Technologies Inc. and intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Our products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please see the Company's website: www.trinitybiotech.com.
| Contact: | Trinity Biotech plc | LifeSci Partners, LLC |
| Louise Tallon | Eric Ribner | |
| (353)-1-2769800 | (1)-646-751-4363 | |
| investorrelations@trinitybiotech.com | ||
| Novus Diagnostics Ltd. | RedChip Companies Inc. | |
| Keith O’Neill | Dave Gentry, CEO | |
| (353)-1-2248831 | (1)-407-644-4256 | |
| keith@novus-dx.com | TRIB@redchip.com |
FAQ
What is Trinity Biotech's (TRIB) investment in Novus Diagnostics worth?
How many shares did Trinity Biotech (TRIB) issue for the Novus investment?
What is the post-investment valuation of Novus Diagnostics after Trinity Biotech's (TRIB) investment?
How fast can Novus Diagnostics' sepsis testing platform deliver results?
